Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
Jeffrey L. Cummings(University of California, Los Angeles), Jingchun Chen(Southwest Minzu University)
Cited by 47
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818
On the path to 2025: understanding the Alzheimer’s disease continuum
|Alzheimer s Research & Therapy|2017|559